ChemDiv, Inc. has entered into a multi-project research and collaboration agreement with Janssen Pharmaceutica and Tibotec Pharmaceuticals, two Johnson & Johnson subsidiaries. ChemDiv will apply its integrated drug discovery expertise and technologies to identify novel small molecules against targets to be jointly agreed upon. For each research project, Janssen or Tibotec will fund certain R&D costs of ChemDiv. ChemDiv will be eligible for certain success milestones. Financial terms were...